Topics

Articles

The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.

Critical Year Ahead for the 340B Drug Pricing Program

A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures. 

The Influence of an Infliximab Biosimilar on Hospital Savings

A difference-in-differences analysis explores the correlation between direct-acting antiviral prescriptions for hepatitis C virus and the softening of state-level limitations. 

Does the Use of Hepatitis C Antivirals Surge Following an Easing of Medicaid Coverage Restrictions?

Videos

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value & Access Advisor, Schoonveld Advisory, offers his thoughts on lower drug prices in the US and provides a sneak peak into future PC features. 

Ed Schoonveld Discusses Drug Pricing in the US and Upcoming Articles

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value and Access Advisor, Schoonveld Advisory and author of The Price of Global Health, explains why pharmaceutical products tend to cost more in the US than the rest of the world. 

Ed Schoonveld Discusses List Prices for Pharmaceuticals in the US Compared to Other Countries

Although AI has simplified various market access processes, this technology does also present its share of barriers, so what can be done to find a happy medium? 

The Synergies in Combining Artificial Intelligence and Market Access 

The two company’s will provide consumers with a platform where they can compare drug prices.

Mark Cuban’s Cost Plus Drugs Partners with Price.com

Patients should not have to wait to access the medication they need.

Fail-First Policies Are Harming Patients

Qualitative study breaks down challenges and priorities of the Medicare Shared Savings Program, as noted by affordable care organizations.